Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + cemiplimab versus pembrolizumab in previously untreated advanced melanoma
NL-OMON59554Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of fianlimab, cemiplimab, pembrolizumab in melanoma, sponsored by Regeneron Pharmaceuticals. Started Oct 2023; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON59554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59554.